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cancer stem-like cells maintaining stemness
and mediating chemotaxis in renal cell
carcinoma
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Abstract
Background: Cancer stem cells (CSCs) are correlated with the initiation, chemoresistance and relapse of tumors.
Notch pathway has been reported to function in CSCs maintenance, but whether it is involved in renal cell
carcinoma (RCC) CSCs maintaining stemness remain unclear. This study aims to explore the effect of Notch
pathway on stemness of CSCs in RCC and the underlying mechanisms.
Methods: The CD133+/CD24+ cells were isolated from RCC ACHN and Caki-1 cell line using Magnetic-activated cell
sorting and identified by Flow cytometry analysis. RT-PCR and immunoblot analyses were used for determining the
stemness maker expression. The effect of Notch pathway on function of CSCs was assessed by self-renewal ability,
chemosensitivity, invasive and migratory ability tumorigenicity in vivo using soft agar colony formation assay,
sphere-forming assay, MTT assay, Transwell assay.
Results: Here, we found that the sorted CD133+/CD24+cells possessed elevated stemness maker CTR2, BCL-2, MDR1,
OCT-4, KLF4, compared with parental cells, as well as enhanced self-renewal ability, stronger resistance to cisplatin and
sorafenib, increased invasion and migration, and higher tumorigenesis in vivo, suggesting the CD133+/CD24+ cells
have the stem-like characteristics of CSCs and thus identified as RCC CSCs. Then the enhanced notch1, notch2,
Jagged1, Jagged2, DLL1 and DLL4 expression were detected in RCC CSCs and blockage of Notch1 or notch2 using
pharmacological inhibitor MRK-003 or its endogenous inhibitor Numb resulted in loss of its stemness features: self-
renewal, chemoresistance, invasive and migratory potential, and tumorigenesis in vivo. Moreover, it is confirmed that
overexpression of notch1 up-regulated CXCR4 inRCC CSCs and augmented SDF-1-induced chemotaxis in RCC CSCs in
vitro, which could be rescued when treatment of CXCR4 inhibitor, suggesting that notch signaling promotes the
chemotaxis of RCC CSCs by SDF-1/CXCR4 axis.
Conclusions: Our results provide a new mechanism of RCC CSCs maintaining stemness via notch pathway as well as a
potential therapeutic target in human RCC.
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Background
Renal cell carcinoma (RCC) is the seventh most com-
mon tumor which is associated with high mortality [1].
RCC accounts for 2–3% of all malignant diseases in
adults [2] The incidence of RCC is rising worldwide and
is ∼ 209,000 cases/year and 102,000 deaths/year [3]. In
addition, The renal cancer 5-year survival rate is stage
dependent and ranges from 8 to 81% for TNM stage IV
and I, respectively [4]. Up to 30% of RCC patients have
metastatic spread at the initial presentation and the 5-
year survival rate drops to 10% in patients with meta-
static disease [5, 6]. Moreover, RCC recurs within the
first 5 years in 40% of patients with an initially localized
disease even after a nephrectomy [1]. Besides, renal can-
cer is extremely resistant to chemotherapy and radiation
therapy [7]. It is gradually accepted that the initiation,
chemoresistance, metastasis and recurrence of tumors
are driven by a small subpopulation of cells endowed
with stem-like properties called cancer stem cells
(CSCs).
The CSCs have self-renewal capacity and differenti-
ation potential, and can reconstruct the phenotypic and
histologic heterogeneity of its parent tumor while trans-
planted in vivo [8, 9]. The CSCs have been isolated and
identified in human renal cell carcinoma from solid
tumor tissues and established cell lines [10–12], using
Magnetic-activated cell sorting (MACS) or flow cytome-
try system based on CD133, CD24, CD105, ALDH1,
Hoechst 33,342 and so on [13]. Although CD133 are
commonly used a screening maker in various tumors
[14, 15], it’s suggested that only CD133 may not be suffi-
cient for CSC identification in RCC [16]. Here, we will
for the first time isolate CD133+/CD24+ cells from RCC
ACHN cell line using MACS and validate the expression
of its stemness-associated makers (CTR2, BCL-2,
MDR1, OCT-4, KLF4) and its stem-like characteristics
including self-renewal capability, chemoresistance, meta-
static potential and tumorigenicity in vivo.
Notch signaling represents a type of direct cell-cell
communication that is essential for regulation of prolif-
eration, apoptosis, and fate decisions of stem cells during
embryonic development [17, 18]. In mammals, there are
5 Notch ligands (Delta-like [Dll] 1, 3, 4, and Jagged 1, 2)
and 4 Notch receptors (Notch 1–4), all of which are type
I transmembrane proteins. Activation of notch receptor
results in NICD releasing into the nucleus, subsequently
activating the related target genes. Increasing evidence
suggest that notch pathway may promote the prolifera-
tion, survival, self-renewal, differentiation, angiogenesis,
and migration of CSCs in several malignancies [19–21].
It is worth to pay attention to that the notch pathway
may play either an oncogenic role or a suppressor in
tumor development based on the special tumor cell con-
text [22]. Although RCC CSCs have been identified, the
expression profile of notch pathway in RCC CSCs and
whether it involves maintaining the stemness of RCC
CSCs and the potential molecular mechanisms remain
unclear.
In this study, the CSCs models derived RCC ACHN
and Caki-1 cell line were established and the expression
pattern of notch1-3 and its ligands in RCC CSCs was
identified. The effects of notch signaling on RCC CSCs
maintaining stemness were investigated. Our results pro-
vided novel mechanisms of RCC CSCs maintenance
controlled by notch signaling pathway.
Methods
Cell lines and medium
Human renal cancer cell lines ACHN and Caki-1 cells
were purchased from ATCC (Manassas, VA) and main-
tained in Dulbecco’s modified Eagle’s medium (DMEM,
GIBCO) supplemented with 10% fetal bovine serum
(FBS, GIBCO) L-glutamine, sodium pyruvate, Penicillin/
Streptomycin, at 37 °C, 5% CO2 condition. To compare
the differences of stemness markers and features, the
sortedCD133+, CD133−, CD133+/CD24−, CD133+/CD24
+ cells or its responding parental cells were cultured in
6-well ultra-low plates (Corning, Acton, USA) contain-
ing serum-free medium DMEM/F12 (Gibco, Carlsbad,
USA), supplemented with commercial hormone mix B27
(Gibco), 20 ng/ml EGF (PeproTech, Rocky Hill, USA),
10 ng/ml bFGF (PeproTech), 0.4% bovine serum albu-
min (Gibco), 4 mg/ml insulin (Gibco), 100 U/ml penicil-
lin and 100 U/ml streptomycin at 37 °C. For CD133
+/CD24+cells or CSCs maintaining culture, after being
cultured for 6 days, the tumor spheres were collected,
dissociated into single cell suspension and resuspended
in fresh medium for serial subcultivation every 6 days.
Magnetic bead cell sorting
For magnetic cell sorting, cells were labeled with CD133
microbeads human antibody (MiltenyiBiotec, Germany).
Sorting was carried out with the Miltenyi Biotec Midi-
MACS Starting Kit according to the manufacturer’s instruc-
tions. Magnetic separation was performed up to three
times to obtain a CD133+ populationmore than 70% pure.
The sorted CD133+ cells were labeled with CD24 microbe-
ads human antibody (MiltenyiBiotec, Germany), and mag-
netic separation was performed up to three times to obtain
a CD133+/CD24+ populationmore than 95% pure. Aliquots
of CD133+ and CD133+/CD24+ sorted cells were evaluated
for purity with Flow cytometry analysis.
Flow cytometry analysis
The cells were dissociated into single cells and labeled
with PE-conjugated anti-CD24 and FITC-conjugated
anti-CD133 (BD PharMingen) at 4 °C for 20 min. Con-
centrations of antibodies were used according to the
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manufacturers’ recommendations. The stained cells were
analyzed with the FACS Calibur machine and Cell Quest
software (BD Biosciences).
Soft agar colony formation assay
Cells were seeded at a density of 1000 cells per well in six
well plates and allowed to grow for 10 days. Clones were
fixed by 4% methanol and dyewith Giemsa (Sigma Aldrich)
and clone numbers were counted microscopically. The
colony formation efficiency = (clone number / inculated cell
number) × 100%.
Sphere-forming assay
To investigate the self-renewal capacity of the sorted
CD133+/CD24+ cells, single cell suspension prepared
from parental cells or the tumor spheres of RCC CD133
+/CD24+ cells was diluted to 1000 cells/ml. One micro-
liter of the single cell suspension was plated in 96-well
ultra-low plates containing 150 ml serum-free medium
per well. Wells containing no cells or more than one cell
were excluded, and those with one cell were marked and
monitored daily under a microscope (Nikon Eclipse
TE2000-S, Nikon, Japan) for 6 days and the colonies
were counted. The self-renewal efficiency = (clone num-
ber / inculated cell number) × 100%.
Quantitative RT-PCR
Total RNA was extracted from cells using TRIzol
Reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions, and then the
RNA was reverse transcribed using the PrimeScript
RT Master Mix Perfect Real Time kit (TaKaRa,
Dalian, China) to obtain the cDNA. Using the cDNA
as the template, a real-time PCR assay was per-
formed using the pairs of primers listed in Table 1.
The 20 μL real-time PCR reaction included 0.5 μL
of cDNA template, 0.25 μL of Primer F, 0.25 μL of
Primer R, 10 μL of RNase-free dH2O, and 8 μL of
2.5× RealMasterMix (SYBR Green I). The reaction
conditions included a pre-denaturation step at 95 °C
for 10 s, and 40 cycles of 95 °C for 15 s and 60 °C
for 60 s. After the reaction, the data were subjected
to statistical analysis.
Invasion, migration and chemotaxis assays
Cells (1 × 106) incubated in serum-free medium were added
on the top of the transwell chamber coated with fresh
Matrigel (Gibco). The medium supplemented with 10%
FBS was added to the bottom of the transwell chamber.
After incubation for 48 h, the cells on top of the chamber
were scraped off using a cotton swab. And the cells in the
bottom of the chamber were fixed and stained with crystal
violet and photographed. The crystal violet was then eluted
and the eluent of each group was measured by a microplate
reader to determine the optical density at 570 nm (OD570).
Migration experiments were performed in polycarbon-
ate transwell inserts (8 μm pores, Corning Costar Corp).
Cells (1 × 106) in 200 μl culture medium were seeded in
the upper chamber and cultured at 37 °C for 6 h. Mi-
grating cells were fixed, stained and detected as invasion
assay. For investigation of chemotaxis, SDF-1α (100 ng/
ml, PeproTech) as inducer was added in the lower
chamber, the other procedures were carried out as mi-
gration assay.
Table 1 Primer sequences of genes
Gene Primer sequence
CTR2 F: 5′- TCCAGGTAGTCATCAGCT -3′
R: 5′- TGGCAGTGCTCTGTGATGTC -3′
BCL-2 F: 5′- CTCCTGACGCTAAGAGCTTCG -3'
R: 5′- CCAGGCTGGAAGGGAAAGAC -3′
MDR1 F: 5′- GGAAGACATGACCAGGTATGC -3′
R: 5′- GCACATCAAACCAGCCTATCTC -3′
OCT-4 F: 5′- TTCAGCCAAACGACCATCT -3′
R: 5′- GCTTTGCATATCTCCTGAAGA -3′
KLF4 F: 5′- CCCACATTAATGAGGCAGC -3′
R: 5′- AGTCGCTTCATGTGGGAGAG -3′
Notch1 F: 5′- CCCGCCAGAGTGGACAGGTCAGTA -3′
R: 5′- TGTCGCAGTTGGAGCCCTCGTTA -3′
Notch2 F: 5′- CCCACAATGGACAGGACA -3′
R: 5′- GAGGCGAAGGCACAATCA -3′
Notch3 F: 5′- TCTCAGACTGGTCCGAATCCAC -3′
R: 5′- CCAAGATCTAAGAACTGACGAGCG -3′
Jagged1 F: 5′- GACACCGTTCAACCTGACAGTATTA -3′
R: 5′- GTCACAGGCATAGTGTCCAAAGA -3′
Jagged2 F: 5′- TCGGGCAGGAACTGTGAGAAGGC -3′
R: 5′- AATCACAGTAATAGCCGCCAATCAGGT -3′
DLL1 F: 5′- AGGGGTGGAGAAGCATCTGAAA -3′
R: 5′- AACCTGCTCGGTCTGAACTCG -3′
DLL3 F: 5′- ACGCCTGGCCTGGCACCTT -3′
R: 5′- CCCTCTAGGCATCGGCATTCACC -3′
DLL4 F: 5′- ACAGTGAAAAGCCAGAGTGTCGG -3′
R: 5′- TGAGCAGGGATGTCCAGGTAGG -3′
β-actin F: 5′- AGGGGCCGGACTCGTCATACT -3′
R: 5′- GGCGGCACCACCATGTACCCT -3′
Vimentin F: 5′- CTTCCGCGCCTACGCCA -3′
R: 5′- GCCCAGGCGAGGTACTCC -3′
Hey1 F: 5′- CATACGGCAGGAGGGAAAG -3′
R: 5′- GCATCTAGTCCTTCAATGATGCT -3′
Hes1 F: 5′- AGTGAAGCACCTCCGGAAC -3′
R: 5′- CGTTCATGCACTCGCTGA -3′
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Cell viability assay
The parental cells, CD133+/CD24+ sorted cells or CD133
+/CD24+ sorted cells transfected with its endogenous in-
hibitor Numb vector pCMV6-AC-GFP-Numb (ORIGENE)
or notch 1 NICD overexpression VectorpCMV6-AC-GFP-
Notch1 (ORIGENE) using lipofectin2000 according to the
manufacturer’s instructions, were treated with cisplatin (0,
5, 10, 15, 20 μM), sorafenib (1, 2, 3 μM), the notch pathway
general pharmacological inhibitor MRK-003, or CXCR4 in-
hibitor AMD3100 (5 μM). Cells treated with the indicated
reagents or samples in exponential growth were plated at a
final concentration of 2 × 103 cells per well in 96-well
plates. The viability of cells was evaluated by MTT assay.
The resistance to cisplatin and sorafenib was determined
after treatment for 24 h. The optical density at 570 nm
(OD570) of each well was measured with an ELISA reader
(ELX-800 type, BioTek).
Western blot
Cells were lysed in cell lysate, and then centrifuged at
12,000 × g for 20 min at 4 °C. The supernatant was col-
lected and denatured. Proteins were separated in 10%
SDS-PAGE and blotted onto polyvinylidene difluoride
membrane (PVDF). The PVDF membrane was treated
with TBST containing 50 g/L skimmed milk at room
temperature for 4 h, followed by incubation with the pri-
mary antibodies: anti-CTR2 (1:200, Novusbio), anti-
BCL-2 (1:500, Immunoway), anti-OCT-4 (1:1000, Pro-
teintech), anti-KLF4 (1:500, Proteintech), anti-MDR1
(1:200, Santa),, anti-Notch1 ICD (1:1000, Abcam), anti-
Notch2 ICD (1:1000, Abcam), anti-Jagged1 (1:500,
Abcam), anti-Jagged2 (1:1000, Abcam), anti-DLL1
(1:500, Abcam), anti-DLL4 (1:500, Abcam), anti-Notch
ICD (1:1000, Cell Signaling), anti-SDF-1 (1:1000,
Abcam), anti-CXCR4 (1:2000, Abcam) and anti-β-actin
(1:1000, Cell signaling) respectively, at 37 °C for 1 h.
Membranes were rinsed and incubated for 1 h with the
correspondent peroxidase-conjugated secondary anti-
bodies. Chemiluminent detection was performed with
the ECL kit (Pierce Chemical, Rockford, IL, USA). The
amount of the protein of interest, expressed as arbitrary
densitometric units, was normalized to the densitomet-
ric units of ß-actin.
Tumorigenicity assay
Animal experiments were performed in strict accordance
with the Guide for the Care and Use of Laboratory Ani-
mals of Hunan Provincial People’s Hospital. The proto-
col was approved by the Committee on the Ethics of
Animal Experiments of Hunan Provincial People’s
Hospital. NOD/SCID mice at age of 3–5 weeks, male,
were maintained in pathogen-free conditions at animal
facility. The Cells pretreated with MRK-003 or Numb
were resuspended in serum-free medium and mixed
with Matrigel at the ratio of 1:1. NOD/SCID mice were
randomly divided into 4 groups (n = 6 per group). Indi-
cated cells of 3 dosages (1 × 105, 1 × 104, and 1 × 103)
were inoculated subcutaneously into the inguinal folds
of NOD/SCID mice. Tumor formation was evaluated
regularly after injection by palpation of injection sites.
Tumor volume was calculated using the equation
(Length ×Weight2)/2. At the end of experiment, the
mice were sacrificed under deep anesthesia with pento-
barbital. The tumors were then dissected and captured.
Immunocytochemistry analysis
The tumor tissue was fixed in 4% paraformaldehyde
overnight. Tissue specimens were then cut at 5 μm
thickness and a standard immunostaining procedure was
performed using antibodies against actived-capase-3 p17
(1: 100, Bioworld Technology, Inc.) and PCNA (1: 50,
ABZOOM). The mean optical density value (D) and area
(A) of brown particles in three visual fields of each sec-
tion were calculated by the Leica Q550 image analysis
system (Leica, German). The expression levels of target
molecules in tissues were evaluated using the formula:
integral density = D × A.
Statistical analysis
All data are presented as mean ± standard deviation. The
means of groups were compared with one-way analysis
of variance, and after checking for equal variance, com-
parisons between two means were performed using the
least significant difference (LSD) method. Student’s t-test
was used for two group’s comparison. Analysis of vari-
ance was used for clinical statistical analyses. In all cases,
P < 0.05 was considered with statistical significant.
Results
Isolation of CD133+/CD24+ cells and characterization of
its stemness markers
To establish of RCC CSCs models from renal carcinomas
cells, the ACHN and Caki-1 cell line cells were subjected
to immunomagnetic bead separation and the purity of
CD133+/CD24+ cells was detected by flow cytometry. As
shown in Fig. 1a and b, the purity of CD133+/CD24+cells
sorted from ACHN and Caki-1 cell lines by immunomag-
netic bead separation reached up to 95.8 and 95.5%, re-
spectively, much higher than that in control parental cells.
Then the relative mRNAs (Fig. 1c and d) and protein
(Fig. 1e and f) expression of CTR2, BCL-2, MDR1, OCT-4,
KLF4,Vimentin and in CD133+/CD24+ cells were deter-
mined by qRT-PCR and western blot analysis, respectively.
The results confirmed that increased CTR2, BCL-2,
MDR1, OCT-4, KLF4, Vimentin and decreased expression
were detected in theCD133+, CD133+/CD24− and CD133
+/CD24+cells of both cell lines, compared to responding
parental cells or CD133−cells. And the expression of Oct-4,
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Bcl-2 and KLF4 in CD133+/CD24+cells of both cell lines
was higher than that in CD133+/CD24− cells . It implies
that the enrichment of CD133+/CD24+cellsfrom ACHN or
Caki-1 cell lines may be beneficial in establishment of the
RCC CSCs models under sphere-forming culture.
CD133+/CD24+ cells have functional features of CSCs
To validate whether the CD133+/CD24+ cells derived
from ACHN or Caki-1 cell lines have stem cell behav-
ior, the soft agar colony formation assay, sphere-
forming assay, invasion and migration by transwell
assay, drug sensitivity by MTT assay and tumorigen-
icity assay in vivo were performed. The results showed
that, compared to renal carcinomas ACHN or Caki-1
parental cells (control, Con), the CD133+/CD24+ cells
of both cell lines have higher clone formation effi-
ciency in soft agar medium (Fig. 2a and b), suggesting
the CD133+/CD24+ cells have growth features of stem
cells; single cells sphere-forming assay results showed
that the CD133+/CD24+ cells could form a greater
number and bigger size of non-adherent spheres
which is called renal carcinomas sphere-forming cells
(SFCs), indicating that the CD133+/CD24+ cells have
stronger self-renewal capability (Fig. 2c and d); the
transwell data confirmed that the CD133+/CD24+ cells
possessed enhanced migratory and invasive capability
(Fig. 2e–h); cisplatin (0, 5, 10, 15, 20 μM) and sorafe-
nib (1, 2, 3 μM) inhibited the proliferation of parental
cells in a dose-dependent manner, but the cell viability
in CD133+/CD24+ cells was significantly higher than
that in parental cells (Fig. 2i–l), suggesting that the
CD133+/CD24+cells have resistance to cisplatin and
sorafenib; moreover, the results of tumorigenicity in
vivo showed that 1 × 104 of CD133+/CD24+ cellscul-
tured in stem cell conditioned medium were sufficient
to induce tumor in NOD/SCID mice, however, the
ACHN or Caki-1 cells cultured in the uniform
medium needed at least 1 × 105cells. Under the condi-
tion of the uniform inoculum size, the tumor inci-
dence in vivo induced by CD133+/CD24+ cells was
higher than that in the parental cells (Table 2). The
above data demonstrate that the CD133+/CD24+ cells
sorted from ACHN or Caki-1 cell lines and main-
tained in stem cell conditioned medium have the clear
functional features of CSCs and thus can be used as
RCC CSCs models for the followed study.
Notch pathway is up-regulated in RCC CSCs
Notch pathways play an important role in regulation of
functions and features of stem cells. Here, we found that
Notch1 and Notch2 mRNA levels in RCC CSCs (CD133
+/CD24+) were significantly higher than that in parental
cells, however, Notch3 mRNA levels in the both types of
cells were not different in statistical significance (Fig. 3a
and b). Then it was discovered that the mRNAs levels of
their corresponding ligandsJagged1 and Jagged2 in RCC
CSCs were also markedly elevated, compared to its ex-
pression in parental cells (Fig. 3c and d). The expression
Fig. 1 Identification of the purity of sorting CD133+/CD24+ cells and its stemness markers. The purity of sorting CD133+/CD24+ACHN a or Caki-1
cells b were detected by flow cytometry analysis. The relative mRNAs (c and d) and protein (e and f) expressions of stemness markers as indicated
were determined by RT-PCR. Control (Con):parental ACHN or Caki-1 cells
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of DLL1, DLL3 and DLL4 in the both types of cells were
compared and the results showed that only DLL1 and
DLL4 were significantly increased in RCC CSCs without
alternation of DLL3 in statistical significance (Fig. 3e
and f). Western blot analysis further confirmed that
Notch1, Notch2, Jagged1, Jagged2, DLL1 and DLL4 pro-
tein levels were also enhanced in RCC CSCs (Fig. 3g and
h). Those results demonstrate that the notch pathways
in RCC CSCs derived from ACHN or Caki-1 cell lines
are abnormal activated.
RCC CSCs maintaining stemness depends upon notch1/2
To validate whether notch1 and notch2 play functional role
in regulation of stemness of RCC CSCs, the general
pharmacological inhibitor MRK-003 and its endogenous in-
hibitor Numb (ORIGENE) of notch pathway were applied.
As shown in Fig. 4a and b, MRK-003 significantly sup-
pressed the expression of notch1, notch2, Hes1 and Hey1
in RCC CSCs. And transfection of Numb vectors markedly
increased Numb expression and significantly inhibited
notch1, notch2, Hes1 and Hey1 in RCC CSCs (Fig. 4c and
d). Inhibition of notch1/2 by MRK-003 or Numb resulted
in down-regulation of the stemness markers CTR2, BCL-2,
OCT-4, KLF4 and MDR1 (Fig. 4e–h), reduced self-renewal
(Fig. 4i and j), invasive and migration capability (Fig. 4k–n),
enhanced sensitivity to cisplatin and sorafenib (Fig. 4o–r),
and decreased tumorigenicity (Fig. 5a and Table 2) in
RCC CSCs. Furthermore, the immunehistological analysis
Fig. 2 Identification of stem-like features of CD133+/CD24+ cells. The clone formation efficiency of CD133+/CD24+ACHN a and Caki-1 b cells was
determined in soft agar. The self-renewal efficiency of CD133+/CD24+ACHN c and Caki-1 d cells was detected by sphere formation assay. The mi-
gratory (e and f) and invasive (g and h) capability of CD133+/CD24+ cells were detected by transwell assay. The sensitivity of CD133+/CD24+cells
to cisplatin (i and j) and sorafenib (k and l) was determined by MTT. *P < 0.05 VS. control; **P < 0.01 VS. control;***P < 0.001 VS. control; Control
(Con):parental ACHN or Caki-1 cells)
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showed that the elevated active caspase3 and reduced
PCNA were detected in the xenografts from RCC CSCs
treated with MRK-003 or transfected with Numb (Fig. 5b
and c), indicating inhibition of notch1/2 increased apop-
tosis and decreased proliferation of RCC CSCs in vivo. It
confirms that maintenance stemness of RCC CSCs, at least,
partly depends upon the activation of notch1 and notch2.
Notch1 contributes to chemotaxis of RCC CSCs by CXCR4/
SDF-1 axis
To investigate the mechanisms underlying notch regula-
tion of chemotaxis of RCC CSCs, the notch1
overexpression RCC CSCs model (CSCs-Notch1) were
successfully constructed and western blot analysis
showed that overexpression of notch1 induced up-
regulation of CXCR4 and SDF-1 (Fig. 6a and b). Treat-
ment of RCC CSCs overexpressing notch1 with CXCR4
inhibitor AMD3100 (5 μM, 24 h) could suppress its in-
vasive and migratory capability (Fig. 6c–f ). It suggests
that notch1 contributes to invasion and migration of
RCC CSCs via up-regulation of CXCR4. As shown in
Fig. 6g and h, overexpression of notch1 increased the
cell viability of RCC CSCs. And addition of CXCR4 in-
hibitor partly rescued overexpression of notch1 mediated
Table 2 Xenotransplantation of cells into NOD/SCID mice









Parental cells 1 × 105 6/6 6/6
1 × 104 4/6 5/6 501.17 ± 46.31 544.67 ± 62.26
1 × 103 1/6 1/6
CSCs 1 × 105 6/6 6/6
1 × 104 6/6 6/6 774.67 ± 54.04 756.67 ± 70.32
1 × 103 3/6 3/6
CSCs + MRK003 1 × 105 5/6 5/6
1 × 104 2/6 3/6 306.17 ± 56.56 378.50 ± 38.34
1 × 103 0/6 1/6
CSCs + Numb 1 × 105 5/6 5/6
1 × 104 3/6 3/6 317.17 ± 82.34 377.50 ± 51.93
1 × 103 0/6 1/6
Fig. 3 Identification of the expression of Notch pathway in RCC CSCs. The relative mRNA levels of notch1-3 (a and b), Jagged1/2 (c and d), DLL1,
DLL3 and DLL4 (e and f) were detected using RT-PCR. (g and h) The up-regulation of notch1/2, Jagged1/2, DLL1/4 protein was validated by west-
ern blot analysis. *P < 0.05 VS. control; **P < 0.01 VS. control;***P < 0.001 VS. control; Control (Con):parental ACHN or Caki-1 cells
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cell viability enhancement. But addition of recombin-
ation protein SDF-1α could further boost overexpression
of notch1 mediated enhancement of cell viability. Those
results indicate that notch1 promotion of proliferation
of RCC CSCs is closely involved in activation of CSCR4/
SDF-1 axis. To investigate the effects of notch1 on
chemotaxis in RCC CSCs, SDF-1α was added in the
lower well in the transwell assays. The results showed
that overexpression of notch1 significantly increased the
migration of ccRCC CSCs. But addition of CXCR4 in-
hibitor partly rescued overexpression of notch1 mediated
enhancement of cell migration (Fig. 6i and k). As shown
in Fig. 6j and l, the expression of CXCR4 decreased in
RCC CSCs in which notch1 signaling was suppressed by
its inhibitor. Those results demonstrate that notch1 in-
creases SDF-1-induced chemotaxis of RCC CSCs via up-
regulation of CXCR4.
Discussion
CSCs have been identified inside different cancers and
considered as the origin of the initiation, growth,
metastasis, chemo-resistance and recurrence of malig-
nant tumors. Clinically, currently used treatment strat-
egies for cancers mostly target somatic tumor cells
rather than CSCs. For the development of efficient ther-
apies against CSCs, it is necessary to isolate and
characterize CSCs from tumor tissues or cell lines, and
reveal its functional features and stemness maintenance
mechanisms. It has been revealed that CD133, CD24,
CD105, Snail, Nanog, Twist, OCT-3/4, CRT2, BCL-
2,MDR1, KLF4 and so on are stemness markers in CSCs
of renal cell carcinoma [13, 16] or other types of tumor
[23, 24]. Here, we successfully isolated and characterized
the CD133+/CD24+ subpopulation of RCC ACHN and
Caki-1 cell line cells using the magnetic-activated cell
sorting (MACS) system and cytometry analysis. And the
increased expression of stemness genes (CTR2, BCL-2,
MDR1, OCT-4, KLF4, Vimentin) were discovered in
CD133+/CD24+ACHN and Caki-1 cells.
CD133 expression is possibly associated with worse
prognosis in tumor patients [25] and has been used as a
stem cell marker in various tumors including renal cell
Fig. 4 The effects of notch signaling on stemness of RCC CSCs. The pharmacological (MRK-003) and endogenous (Numb) notch inhibitor
suppressed the expression of notch1, notch2, Hes1 and Hey1 mRNAs (a, b, c and d), and stemness markers mRNAs (e and g) and proteins (f and
h), decreased the self-renewal efficiency (i and j), invasion (k and l), migration (m and n), and sensitivity to cisplatin (o and p) and sorafenib (q
and r) in RCC CSCs. *P < 0.05 VS. control; **P < 0.01 VS. control;***P < 0.001 VS. control; Control (Con): the RCC CSCs treated without inhibitor)
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carcinoma, however, CD133 as a single marker may not
be sufficient for CSC identification in RCC [16]. Galleg-
giante and his colleagues [26] found that the CD133
+/CD24+ tumor cells isolated from human renal cell car-
cinoma tissues possessed the CSCs characteristics such
as self-renewal ability and multi-differentiation potential.
Our results further confirmed that CD133+/CD24+
tumor cells isolated from RCC ACHN or Caki-1 cell line
cells expressed by higher level of stemness marker and
possessed self-renewal ability validated by soft agar col-
ony formation and spheres formation assays, resistance
to cisplatin and sorafenib, stronger ability to form tumor
in vivo, and higher invasive and migratory potential vali-
dated bytranswell assay. Moreover, CD133+/CD24+ RCC
ACHN cells showed stronger self-renewal ability com-
pared to its CD133+ tumor cells (data not shown). It
suggests that those sorting ccRCC CD133+/CD24+cells
have stemness markers as well as functional properties
Fig. 5 The effects of notch signaling on proliferation of RCC CSCs in vivo. a The pharmacological (MRK-003) and endogenous (Numb) notch
inhibitor suppressed the growth of RCC CSCs in NOD/SCID mice. (b and d) Immunohistochemistry analysis showed that increased actived-
caspase-3 and decreased PCNA were detected in tumor tissue from RCC CSCst reated with RAK-003 or transfected with Numb vector.*P < 0.05 VS.
control; **P < 0.01 VS. control;***P < 0.001 VS. control; Control (Con): the RCC CSCs treated without inhibitor)
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of CSCs and were thus used as CSCs model of RCC in
the subsequent functions and mechanisms investigation.
Notch pathway, comprising 4 receptors (Notch 1–4)
and 5 ligands (DLL-1, DLL-3, DLL-4, Jagged-1 and
Jagged-2) in adjacent cells [27], plays an important role
in regulation of cellular communication in embryogen-
esis and stemness, differentiation and growth of stem
cell [28, 29]. Notch may play a role in tumourigenesis by
inhibiting differentiation, promoting survival, or acceler-
ating proliferation. The aberrant activation of notch sig-
naling pathway may contribute to development of some
tumors including melanoma, glioma, breast carcinoma,
colon carcinoma, cervical cancer and so on [30, 31]. But
it is also reported that notch signaling may serve as a
suppressor in a few tumors, for example, forebrain
tumor subtypes [22]. Therefore, the special roles of
notch pathway in development of tumor may depend
upon tumor types. Studies indicate that notch signaling
pathway takes part in regulation of stemness properties
and functions including self-renewal, differentiation,
chemosensitivity, invasion and migration in CSCs [28]
derived from hepatocellular carcinoma [32], colorectal
carcinoma [33], pancreatic cancer [34], esophageal
adenocarcinoma [35], glioblastoma [36], etc. It is
Fig. 6 The effects of overexpression of notch 1 on chemotaxis of RCC CSCs induced by SDF-1. (a and b) Increased SDF-1 and CXCR4 induced by
overexpression of notch1 in RCC CSCs. CXCR4 inhibitor AMD3100 decreased invasion (c and d) and migration (e and f) of RCC CSCs overex-
pressed by notch1. (g and h) Addition of SDF-1α and AMD3100 affected the cell viability of RCC CSCs overexpressed by notch1. (i and k) Addition
of SDF-1α in the lower well in transwell assay, AMD3100 reduced overexpression of notch1-mediated chemotaxis in RCC CSCs. (j and l) Suppres-
sion of notch 1 induced by its inhibitor decreased CXCR4 in RCC CSCs. *P < 0.05 VS. indicated group; **P < 0.01 VS. indicated group;***P < 0.001 VS.
indicated group
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reported that notch1, notch3 and jagged1 are highly
expressed in RCC and blockage of notch signaling can
suppress its growth [37, 38]. And high jagged1 expres-
sion predicts poor outcome in RCC [39]. However, the
expression pattern, special functions and action mecha-
nisms of notch pathway in RCC CSCs remain elusive.
Therefore, we examined the expression of the 4 recep-
tors and 5 ligands of notch pathway in RCC CSCs de-
rived from ACHN and Caki-1 cells and found that
Notch1, Notch2, Jagged1, Jagged2, DLL1 and DLL4 were
significantly enhanced in RCC CSCs, suggesting that
notch signaling pathways in RCC CSCs are aberrant ac-
tivated. While notch1/2 was suppressed by its pharma-
cological inhibitor MRK-003 or its endogenous inhibitor
Numb, the expression of stemness markers (CTR2,
BCL-2, OCT-4, KLF4 and MDR1) and stemness func-
tional properties (self-renewal, high invasion and migra-
tion, resistance to cisplatin and sorafenib and strong
tumorigenicity) were inhibited in RCC CSCs. It confirms
that RCC CSCs sustaining stemness, at least, partly de-
pends upon the activation of notch1/2 possibly by
Jagged1, Jagged2, DLL1 or DLL4 in adjacent CSCs,
strongly supporting a crucial role of the notch pathways
inRCC CSCs subset maintenance.
It is well known that BCL-2 is a member of anti-
apoptotic protein family and its up-regulation will favor
RCC CSCs survival via resistance to drugs or cytokines
induced pro-apoptotic action. Up-regulation of drug re-
sistance gene including MDR1 is associated with in-
creased chemo-resistance of RCC CSCs. OCT-4 may
play a critical role in CSCs maintaining self-renewal
[40]. KLF4 is an important transcript factor in induction
of dedifferentiation [41]. OCT-4 and KLF4 function in
sustaining the pluripotent of stem cell. Blockage of notch
signaling in RCC CSCs led to the down-regulation of
anti-apoptotic gene, drug resistance gene and pluripo-
tent gene and loss of its stemness characteristics and
functions. It implies that the aberrant activation of notch
signaling could up-regulated those stemness-associated
genes are possible mechanisms underlying notch path-
way serves as a crucial promoter in RCC CSCs
maintenance.
The high mortality of RCC diseases correlates with its
significant propensity to metastasize in an organ specific
manner. Enhanced CXCR4 expression was detected in
several human renal carcinoma samples, while only min-
imal CXCR4 expression was detected in normal kidney
tissues [42]. It has been suggested that CXCR4 expres-
sion by tumor cells, plays a critical role in cell metastasis
by a chemotactic gradient to organs expressing the lig-
and SDF-1. SDF-1 as the receptor of CXCR4 promotes
CXCR4-expressing RCC cells metastasis to specific
organ expressing SDF-1 [43]. Moreover, our data further
demonstrate that notch1 promotes SDF-1-induced
chemotaxis of RCC CSCs via up-regulation of CXCR4.
Our findings are consistent with the previous reports
that CXCR4 functions in maintenance of renal cell
carcinoma-initiating cells derived from renal carcinoma
cell line RCC-26 an RCC-53 [44] and its expression in
mesenchymal stem cells is regulated by Notch signaling
[45]. Thus, it is suggested that aberrant activation of
notch1 signaling may enhance invasive and migratory
ability of RCC CSCs that may promote its metastasis to
special origin. Our results also showed that overexpres-
sion of notch1 resulted in increased SDF-1 in RCC
CSCs. Whether this implies SDF-1/CXCR4 axis play a
functional role in itself homing and proliferation in
microenviroment need further study.
Taken together, our findings demonstrate the crucial
role of notch pathway in RCC CSCs maintenance and
provide potent preclinical evidence supporting notch sig-
naling pathway as an optional target for eliminating the
CSCs in RCC tissues. Thus, it is a promising therapeutic
option to combine blockage of notch signaling pathway
and the standard chemotherapy mainly targeting bulk
tumor. This strategy may offer the hope to partly resolve
the problems such as metastasis, recurrence and chemore-
sistance in clinical treatment of RCC and greatly improve
the quality of life in patients with RCC.
Conclusions
The research confirmed that notch1, notch2, Jagged1,
Jagged2, DLL1 and DLL4 were over-expressed in RCC
CSCs, and blockage of Notch1 or notch2 using pharmaco-
logical inhibitor MRK-003 or its endogenous inhibitor
Numb resulted in partial loss of its stemness features: self-
renewal, chemoresistance, invasive and migratory potential,
and tumorigenesis in vivo. Moreover, it is confirmed that
notch signaling promotes the chemotaxis of RCC CSCs by
SDF-1/CXCR4 axis. Our results provide a new mechanism
of RCC CSCs maintaining stemness via notch pathway as
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